Deals this week: Allergan, BioCryst Pharmaceuticals, Oncodesign
Allergan Funding SCS, an indirect subsidiary of Irish biopharmaceutical company Allergan, intends to raise funds through a registered public offering of euro-denominated senior unsecured notes with maturities of up to 12 years in multiple tranches.
The proceeds are intended to be used partly for purchasing the existing USD notes validly tendered and accepted for purchase, while the remaining will be used for general corporate purposes.
US-based biotechnology company BioCryst Pharmaceuticals intends to issue 11.7 million shares of its common stock to public.
The company has filed a registration statement with the US Securities and Exchange Commission (SEC) regarding the same.
French biotechnology company Oncodesign has reached an agreement to acquire certain businesses of Bertin Technologies’ subsidiary, Bertin Pharma.
The acquisition includes service businesses in metabolism, pharmacokinetics, bio-analysis and translational medicine activities.
Chinese pharmaceutical company Hubei Jumpcan Pharmaceutical intends to raise up to ¥860m ($124.57m) by issuing convertible bonds to public.
Cytokinetics has announced the pricing for its proposed underwritten public offering of shares as $14.25 per share.
The issue will include 5.26 million shares to raise $75m in gross proceeds.
Underwriters to the offering will be granted a 30-day option to purchase up to an additional 789,000 shares.
The offering is expected to be completed on 12 May.